scholarly journals Effect of High‐Dose Acyclovir on Survival in Allogeneic Marrow Transplant Recipients Who Received Ganciclovir at Engraftment or for Cytomegalovirus pp65 Antigenemia

1998 ◽  
Vol 178 (4) ◽  
pp. 1153-1157 ◽  
Author(s):  
Michael Boeckh ◽  
Ted A. Gooley ◽  
Raleigh A. Bowden
Keyword(s):  
Marrow Transplant ◽  
High Dose ◽  
Transplant Recipients ◽  
Pp65 Antigenemia ◽  
Allogeneic Marrow

scholarly journals Foscarnet for prevention of cytomegalovirus infection in allogeneic marrow transplant recipients unable to receive ganciclovir

1997 ◽  
Vol 20 (6) ◽  
pp. 491-495 ◽  
Author(s):  
C Ippoliti ◽  
A Morgan ◽  
D Warkentin ◽  
K van Besien ◽  
R Mehra ◽  
...  
Keyword(s):  
Cytomegalovirus Infection ◽  
Marrow Transplant ◽  
Transplant Recipients ◽  
To Receive ◽  
Allogeneic Marrow

scholarly journals A Multisite Trial Comparing Two Cytomegalovirus (CMV) pp65 Antigenemia Test Kits, Biotest CMV Brite and Bartels/Argene CMV Antigenemia

2000 ◽  
Vol 38 (4) ◽  
pp. 1430-1433 ◽  
Author(s):  
Kirsten St. George ◽  
Molly J. Boyd ◽  
Steven M. Lipson ◽  
David Ferguson ◽  
G. Frank Cartmell ◽  
...  
Keyword(s):  
Organ Transplant ◽  
Marrow Transplant ◽  
Transplant Recipients ◽  
Blood Leukocytes ◽  
Predictive Values ◽  
Cell Counts ◽  
Pp65 Antigenemia ◽  
Blood Specimens ◽  
Sensitivity Specificity ◽  
Cmv Antigenemia

A total of 513 blood specimens, predominantly from organ transplant recipients, human immunodeficiency virus-positive patients, and bone marrow transplant recipients, were tested for cytomegalovirus (CMV) by culture and pp65 antigenemia across four test sites. Peripheral blood leukocytes were examined by using both the Biotest CMV Brite and the Bartels/Argene CMV Antigenemia kits. A total of 109 specimens were positive for CMV, 106 (97%) were positive by antigenemia, and 34 (31%) were positive by culture. According to the manufacturers' instructions, 150,000 cells were applied per slide for the Biotest kit and 200,000 cells per slide for the Bartels kit. A total of 93 specimens (88%) were positive by the Biotest kit, and 86 (81%) were positive by the Bartels kit. In specimens found to be positive by only one kit, the positive cell counts were low (median, 1; range, 1 to 7). When the data from all four sites were combined and analyzed, there was no statistical difference between the performance of the two kits; the Biotest and Bartels kits were found to be equivalent in sensitivity, specificity, and positive and negative predictive values for the detection of CMV pp65 antigenemia.

scholarly journals Transfusion support using filtered unscreened blood products for cytomegalovirus-negative allogeneic marrow transplant recipients

1998 ◽  
Vol 22 (6) ◽  
pp. 575-577 ◽  
Author(s):  
AB Narvios ◽  
D Przepiorka ◽  
J Tarrand ◽  
K-W Chan ◽  
R Champlin ◽  
...  
Keyword(s):  
Marrow Transplant ◽  
Transplant Recipients ◽  
Blood Products ◽  
Allogeneic Marrow

Quantitative Analysis of Cytomegalovirus (CMV) Viremia Using the pp65 Antigenemia Assay and the COBAS AMPLICOR CMV MONITOR PCR Test after Blood and Marrow Allogeneic Transplantation

2000 ◽  
Vol 38 (12) ◽  
pp. 4356-4360 ◽  
Author(s):  
G. Boivin ◽  
R. Bélanger ◽  
R. Delage ◽  
C. Béliveau ◽  
C. Demers ◽  
...  
Keyword(s):  
Allogeneic Transplantation ◽  
Marrow Transplant ◽  
Transplant Recipients ◽  
Ganciclovir Therapy ◽  
Pp65 Antigenemia ◽  
Pcr Assays ◽  
Short Courses ◽  
Roche Diagnostics ◽  
Pcr Test ◽  
Qualitative Pcr

The performance of a commercially available qualitative PCR test for plasma (AMPLICOR CMV Test; Roche Diagnostics) and a quantitative PCR test for plasma and leukocytes (COBAS AMPLICOR CMV MONITOR Test; Roche Diagnostics) was evaluated with samples from 50 blood or marrow allogeneic transplant recipients who received short courses of sequential ganciclovir therapy (2 weeks intravenously followed by 2 weeks orally) based on a positive cytomegalovirus (CMV) pp65 antigenemia (AG) assay. The number of persons with a positive CMV test was significantly higher for leukocyte-based assays (AG, 67.5%; PCR, 62.5%) compared to both quantitative and qualitative PCR tests of plasma (42.5 and 35%, respectively). One person developed CMV disease during the study despite a negative AG assay; in this particular case, all PCR assays were found to be positive 10 days before his death. There was a trend for earlier positivity after transplantation and more rapid negativity after initiation of ganciclovir for the tests performed on leukocytes. The mean number of CMV copies as assessed by PCR was significantly higher in leukocytes than in plasma (P = 0.02). Overall, excellent agreement (kappa coefficient, >0.75) was found only between the two PCR assays (qualitative and quantitative) based on plasma. These results suggest that either the pp65 AG assay or the COBAS AMPLICOR CMV MONITOR Test using leukocytes could be used to safely monitor CMV viremia in related allogeneic blood or marrow transplant recipients. Such a strategy will result in preemptive treatment for about two-thirds of the persons with a relatively low rate (<33%) of secondary viremic episodes following short courses of ganciclovir therapy.

Sign in / Sign up

Export Citation Format

Share Document